Azeria Therapeutics Raises £32.0M in Series B Financing

Azeria Therapeutics, a Cambridge, UK-based drug discovery company developing treatments for hormone-resistant breast cancer patients, raised £32 million in Series B financing led by Syncona. The round will be used to take the company's lead program into the clinic and explore a pipeline of further programs in oncology. Azeria's approach is based on targeting FOXA1, an essential pioneer factor that has been shown to be pivotal in the tumor growth, progression, and maintenance of estrogen receptor positive luminal breast cancer.

Azeria Therapeutics Secures £32 Million Series B Funding to Advance Breast Cancer Treatment

Azeria Therapeutics is a Cambridge, UK-based drug discovery company developing treatments for hormone-resistant breast cancer patients. The company was founded in 2017 by Sixth Element Capital, manager of the CRT Pioneer Fund and Cancer Research UK’s Commercial Partnerships team, and is led by Stephen Myatt, Chief Executive Officer. Azeria's approach is based on the work of Professor Jason Carroll at the Cancer Research UK Cambridge Institute, University of Cambridge, whose research has led to a new approach to target FOXA1 driven cancer. FOXA1 is an essential pioneer factor that has been shown to be pivotal in the tumor growth, progression, and maintenance of estrogen receptor positive luminal breast cancer.

Azeria Therapeutics is a UK-based drug discovery company developing treatments for hormone-resistant breast cancer patients.

6 years ago

Azeria Therapeutics Secures £32 Million Series B Funding to Advance Breast Cancer Treatment

ProblemHealthcare

Solution

Covered on